### **Monterey County EMS System Policy**



Policy Number: 4520 Effective Date: 5/23/2023 Review Date: 6/30/2024

# MEDICATION FOR ADDICTION TREATMENT (MAT)OPIOID WITHDRAWAL TREATMENT (BUPRENORPHINE)

#### I. <u>INTRODUCTION PURPOSE</u>

Buprenorphine may be utilized for stable To provide guidance for treating patients who are (a) exhibiting signs or symptoms of opioid withdrawal, and/or (b) for patients who have been are successfully resuscitated following an opioid overdose, including the administration of naloxone. ALS providers may activate a prehospital-based MAT program, which allows paramedics to administer buprenorphine AND link the patient with a hospital treatment program.

This is a Tri-County (Monterey/Santa Cruz/San Benito) effort to reduce both all-cause and overdose mortality among individuals with Opioid Use Disorder (OUD). Offering buprenorphine treatment to individuals experiencing opioid withdrawal or to those who experience a nonfatal opioid overdose provides an opportunity to reduce opioid overdose fatalities.

At this time, we are limiting tThis optional scope of practice item is currently limited to AMR paramedics only, although we anticipate extending this project to all ALS 9-1-1 transport providers in the future. This limited roll-out will allow us to study cost, utilization, and overall effectiveness before considering whether to expand the local optional scope of practice (LOSOP) authorization to all ALS providers.

#### II. ASSESS FOR EXCLUSION CRITERIA-CLARIFICATION

See the EMS Buprenorphine (Opioid Withdrawal) Flowchart (below). While patients who are pregnant are excluded from administration of buprenorphine, breastfeeding are approved for administration.

A. Patients with any of the following **exclusion criteria** should not receive buprenorphine:

- No opioid withdrawal signs of symptoms
- Under 16 years of age
- Any methadone use within the last 10 days
- Severe medical illness (sepsis, respiratory distress, etc.)
- Altered mental status and unable to give consent or comprehend potential risks and benefits of receiving buprenorphine
- Clinical Opioid Withdrawal Scale score (COWS score) < 8

Patients who are currently <u>altered intoxicated or show signs of recent</u>
use of \_\_\_\_\_\_benzodiazepine, alcohol or other intoxicants which has
resulted in an altered mental status should be

excluded from administration.



#### III. ADMINISTRATION

- A. See the EMS Buprenorphine (Opioid Withdrawal) Flowchart (below).
- B. Consider Base Contact for complex cases or additional support.
- C. Offer patient buprenorphine and counseling on treatment options.
- D. If patient consents to treatment, administer buprenorphine 16 mg sublingual. (Both 8 mg strips can be given at the same time.)
- E. Reassess after 10 minutes.
- F. If symptoms worsen or persist, administer buprenorphine 8 mg sublingual. (Do not exceed a total maximum dose of 24 mg sublingual.)

Both doses/strips of buprenorphine may be given concurrently (i.e., the administration of 16mg may be given at the same time).


See the EMS Buprenorphine (Opioid Withdrawal) Flowchart (below).

Both doses/strips of buprenorphine may be given concurrently (i.e., the administration of 16mg may be given at the same time).


#### IV. TRANSPORT

- A. Recommend transport to a local California Bridge hospital. All seven 7 Tri-County based Hhospitals are CA Bridge Sites and appropriate destinations for transport: Community Hospital of Monterey Peninsula; Watsonville Community Hospital; Dominican Hospital; Mee Memorial; Natividad Medical Center; Salinas Valley Health; and Hazel Hawkins Hospital.
- A.B. If patient declines transport, obtain contact information if possible and inform them that a Substance Use Navigator may contact them to provide further support.

## EMS Buprenorphine (Opioid Withdrawal) Flowchart



Recentacting the 'Opioid Protocol Physician' for subsequent dosing is not required.



Materials provided with permission from the California Department of Health Care Services, Public Health Institute, CA Bridge Program. More resources available www.CABridge.org

If the COWS QR Code (above) or website is unavailable, please use the COWS form below.

PATIENT NAME:	DATE OF ASSESSMENT:
PATIENT DATE OF BIRTH:	MEDICAL RECORD NUMBER:

# Clinical Opioid Withdrawal Score (COWS)

COWS is not required prior to starting buprenorphine, but it can help ensure the patient is ready for the first dose. For each item, write in the number that best describes the patient's signs or symptoms. Rate only the apparent relationship to opiate withdrawal. For example: If heart rate is increased because the patient was jogging just prior to assessment, the increased pulse rate would not add to the score.

Enter scores at time zero, 30 minutes after fi	rst dose, 2 hours after first dose, etc.	Time:	Time:	Time:	Time:
Resting Pulse Rate: Record beats per minute after	er patient is sitting or lying down for one minute				
• 0 - pulse rate 80 or below • 1 - pulse rate 81–100	2 - pulse rate 101–120     4 - pulse rate greater than 120				
Sweating: Over past ½ hour not accounted for b	y room temperature or activity				
O - no chills or flushing 1 - subjective chills or flushing 2 - flushed or observable moistness on face	3 - beads of sweat on brow or face     4 - sweat streaming off face				
Restlessness: Observation during assessment • 0 - able to sit still	3 - frequent shifting or extraneous movement of legs/arms				
• 1 - reports difficulty sitting still, but is able to do so	• 5 - unable to sit still for more than a few seconds				
Pupil size					
0 - pupils pinned or normal size for light     1 - pupils possibly larger than normal for light	2 - pupils moderately dilated     5 - pupils dilated that only rim of the iris is visible				
Bone or joint aches: If patient was having pain pa ttributed to opiate withdrawal is scored	reviously, only the additional component				
O - not present 1 - mild/diffuse discomfort 2 - patient reports severe diffuse aching of joints/muscles	4 - patient is rubbing joints or muscles and is unable to sit still because of discomfort				
Runny nose or tearing: Not accounted for by colo	d symptoms or allergy				
O - none present 1 - nasal stuffiness or unusually moist eyes	2 - nose running or tearing     4 - nose constantly running or tears streaming down cheeks				
Gl upset: Over last ½ hour	2 - nausea or loose stool				
0 - no Gl symptoms     1 - stomach cramps	3 - vomiting or diarrhea     5 - multiple episodes of diarrhea or vomiting				
Tremor: Observation of outstretched hands					
0 - no tremor     1 - tremor can be felt, but not observed	2 - slight tremor observable     4 - gross tremor or muscle twitching				
Yawning: Observation during assessment  O - no yawning  1 - yawning once or twice during assessment	2 - yawning three or more times during assessment     4 - yawning several times/minute				
Anxiety or irritability	2 - patient obviously irritable or anxious				
0 - none     1 - patient reports increasing irritability or anxiousness	4 - patient so irritable or anxious that participation in the assessment is difficult				
Gooseflesh skin	3 - piloerection of skin can be felt or hairs standing up on arms				
• 0 - skin is smooth	• 5 - prominent piloerection				
start buprenorphine	TOTAL				
in the ED is COWS≥8	OBSERVER INITIALS				

**END OF POLICY** 

John Beuerle, M.D.

**EMS Medical Director** 

Teresa Rios

**EMS Bureau Chief**